Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 12/20 | 1.00 |
| ▸ | LDHB | P07195 | 11/20 | 1.00 |
| ▸ | ALB | P02768 | 6/20 | 1.00 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426471 | 1.00 | LDHA (1.00) | LDHALDHBALBDHODHCSNK2A1 | |
| SCHEMBL19202488 | 0.83 | LDHA (0.77) | LDHALDHBALBDHODHCSNK2A1 | |
| SCHEMBL7181495 | 0.81 | LDHA (1.00) | LDHALDHBALBDHODHCSNK2A1 | |
| SCHEMBL7173943 | 0.81 | LDHA (1.00) | LDHALDHBALB | |
| SCHEMBL26027710 | 0.80 | LDHA (0.66) | LDHALDHBALBDHODH | |
| SCHEMBL19202493 | 0.80 | LDHA (0.72) | LDHALDHBALBDHODHCSNK2A1 | |
| SCHEMBL8460263 | 0.79 | LDHA (0.65) | LDHALDHBALB | |
| SCHEMBL2622271 | 0.77 | ALB (1.00) | LDHALDHBALB | |
| SCHEMBL29555202 | 0.77 | ALB (1.00) | LDHALDHBALB | |
| SCHEMBL8459960 | 0.76 | ALB (1.00) | LDHALDHBALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366544-A1 | REGULATION OF MUTANT TERT BY BRAF V600E/MAP KINASE PATHWAY THROUGH FOS/GABP IN HUMAN CANCER | UNIV JOHNS HOPKINS (US) | 2024-11-07 | — | — | US | claimed |
| US-11911356-B2 | Regulation of mutant TERT by BRAF V600E/map kinase pathway through FOS/GABP in human cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-27 | — | — | US | claimed |
| WO-2023034530-A1 | METHODS OF IMPROVING GROWTH AND FUNCTION OF IMMUNE CELLS | TEON THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| CN-116194479-B | Anti-TAU antibodies | GT创新公司 | 2026-05-22 | — | — | CN | disclosed |
| US-12624096-B2 | Anti-tau antibodies and methods of use thereof | Gtinvent Limited (GB) | 2026-05-12 | — | — | US | disclosed |
| US-20260026508-A1 | Seed Treatment Formulations and Methods of Use | PUNA BIO CORP (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4683579-A1 | RELIEVE BACK PAIN AND/OR REBUILDING INTERVERTERAL DISC | Yeung, Jeffrey E. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4655003-A1 | METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS INFECTION | Leyden Laboratories B.V. (NL) | 2025-12-03 | — | — | EP | disclosed |
| US-12478601-B2 | Dietary product devoid of at least two non essential amino acids | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-11-25 | — | — | US | disclosed |
| US-20250355001-A1 | METHOD FOR DETECTING A TAU PROTEIN FRAGMENT IN A SAMPLE | GTINVENT LTD (GB) | 2025-11-20 | — | — | US | disclosed |
| US-20250290152-A1 | GENETIC TRIO OF BRAF AND TERT MUTATIONS AND RS2853669TT IN PAPILLARY THYROID CANCER AGGRESSIVENESS | THE JOHNS HOPKINS UNIVERSITY | 2025-09-18 | — | — | US | disclosed |
| EP-4218751-A2 | DIETARY PRODUCT DEVOID OF AT LEAST TWO NON ESSENTIAL AMINO ACID | Cancer Research Technology Ltd (GB) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023135201-A1 | METHOD FOR DETECTING A TAU PROTEIN FRAGMENT IN A SAMPLE | Gtinvent Limited (GB) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023135200-A1 | METHOD FOR DETECTING A TAU PROTEIN IN A SALIVA SAMPLE | Gtinvent Limited (GB) | 2023-07-20 | — | — | WO | disclosed |
| CN-116194479-A | anti-TAU antibodies | GT创新公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4178980-A1 | ANTI-TAU ANTIBODIES | Gtinvent Limited (GB) | 2023-05-17 | — | — | EP | disclosed |
| WO-2023034530-A1 | METHODS OF IMPROVING GROWTH AND FUNCTION OF IMMUNE CELLS | TEON THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-3541774-B1 | NOVEL USE OF PHENYL PHOSPHINIC ACID | DSM IP ASSETS BV (NL) | 2022-11-30 | — | — | EP | disclosed |
| US-11506906-B2 | Head-up display system | MAXELL, LTD. (JP) | 2022-11-22 | — | — | US | disclosed |
| EP-3541775-B1 | NOVEL PROCESS FOR THE MANUFACTURE OF GAMMA,DELTA-UNSATURATED KETONES | DSM IP ASSETS BV (NL) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478601-B2 | Dietary product devoid of at least two non essential amino acids | FABP2, BCAT2, BCAT1 | LDHA 1661/4885LDHB 1693/4885ALB 354/4885 |
| US-12624096-B2 | Anti-tau antibodies and methods of use thereof | MAPT, PSEN1, PSEN2 | LDHA 3092/4885LDHB 2692/4885ALB 1882/4885 |
| US-20260026508-A1 | Seed Treatment Formulations and Methods of Use | PGLS, GNE, GALE | LDHA 3594/4885LDHB 4200/4885ALB 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.